Pacira Phase 3 Results For EXPAREL Demonstrated Statistical Significance For Both Primary And Secondary Endpoints In Upper Extremity Study But Did Not For The Lower Extremity Study, Timing For Resubmission Of Supplemental NDA Remains On Track